After a staggering two years of unprecedented disruption and innovation, there’s no longer questions surrounding whether pharma can realize exceptional change. What’s less certain, however, is where and how pharma will direct its efforts to achieve ground-breaking transformation over the next five years.  

In Reuters Events’ exclusive new report, ‘Pharma Predictions 2022-2027’ leaders across the industry have shared their predictions for pharma’s top priorities for the coming years, so you can see where our collective path may be headed. 

In addition to forecasts from our very own Reuters Events Pharma team, read predictions from leading experts including:  

Zhen Su, CEO, Marengo Therapeutics          

Oscar Segurado, Chief Medical Officer, ASC Therapeutics          

Eddie Power, VP, North America Medical Affairs, Pfizer  

Victoria DiBiaso, Global Head, Patient Informed Development & Health Value Translation, Sanofi        

Haider Alleg, Global Head of Digital, Ferring    

Mark Montgomery, Head, Business Insights & Execution, Commercial Acceleration, Novartis    

Keri Yale, Head, Patient Affairs & Engagement, Boehringer Ingelheim  

Trellis Usher, Founder & CEO, Nova Health Labs  

See what our experts have to say and think on what your priorities are for 2022 and beyond – read your FREE copy today!